rs4129267 — IL6R IL6R intronic multi-trait variant

IL6R Intronic Tag Variant — When Your Intron Tells the Story Your Exon Already Told

Genome-wide association studies routinely identify non-coding variants as the top signals at causal loci. rs4129267 is a textbook case: an intronic variant in the IL-6 receptor gene (IL6R) on chromosome 1q21 that has no direct protein-changing effect, but is in perfect linkage disequilibrium (r²=1) with rs2228145, the missense variant that alters amino acid 358 from aspartate to alanine (Asp358Ala) and substantially changes how the IL-6 receptor is shed from cell surfaces. Carrying the T allele at rs4129267 is biologically equivalent to carrying the risk-associated 358Ala allele — every T-allele chromosome also carries 358Ala at rs2228145.

The Mechanism

IL-6 signals through two distinct modes: classical signaling¹¹ classical signaling
Classical IL-6 signaling requires membrane-bound IL-6Rα on the target cell. Only hepatocytes, monocytes, and certain lymphocytes express this receptor, making them the primary targets of classical IL-6 action: acute-phase protein production, CRP synthesis, and Th17 polarization via the cell-surface receptor, and trans-signaling²² trans-signaling
Trans-signaling uses the shed, soluble form of IL-6Rα (sIL-6Rα) to activate cells that lack membrane-bound receptor, including endothelial cells, smooth muscle cells, neurons, and Th2-permissive immune progenitors — dramatically broadening IL-6's reach via the shed soluble receptor. The Asp358Ala substitution tagged by rs4129267-T increases ectodomain shedding by the ADAM10 and ADAM17 metalloproteases. The net result per T allele: circulating sIL-6R rises by approximately 34.6%, membrane IL-6Rα density on CD4+ T cells and monocytes falls by up to 28%, classical signaling weakens, and trans-signaling strengthens. CRP and fibrinogen decrease; Th2-permissive responses increase.

The intronic position of rs4129267 means it has no direct functional role. It tags the Asp358Ala functional variant — its value as a marker arises entirely from its co-inheritance with rs2228145-C on the same chromosome.

The Evidence

The Ferreira et al. Lancet GWAS (2011)³³ Ferreira et al. Lancet GWAS (2011)
2,669 Australian asthmatics and 4,528 controls, combined with GABRIEL consortium and four in-silico replication cohorts; total n=57,800 identified rs4129267 as a genome-wide significant risk locus for asthma within IL6R (OR 1.09, combined p=2.4×10⁻⁸). This was the landmark study establishing IL6R as an asthma susceptibility gene and the study that first raised the possibility that IL-6 receptor antagonists (tocilizumab) might have therapeutic potential in a genotype-stratified asthma population.

Hawkins et al. (JACI, 2012)⁴⁴ Hawkins et al. (JACI, 2012)
Lung function study in asthmatic adults from the Severe Asthma Research Program (SARP) and Chicago Subcohort of the Chicago Asthma Genetics Study (CSGA); n=355 European-ancestry asthmatics confirmed that rs4129267 and rs2228145 are in perfect LD (r²=1), establishing that any genetic finding at one variant directly applies to the other. The 358Ala allele (tagged by rs4129267-T) associated with reduced FEV1, FVC, and FEV1/FVC ratio across both cohorts (combined p=0.003), and was enriched in severe asthma phenotypic clusters.

The Revez et al. study (Genes Immun, 2013)⁵⁵ Revez et al. study (Genes Immun, 2013)
16,705 asthmatics and 30,809 controls from the Australian Asthma Genetics Consortium and international replication cohorts used rs4129267 as the proxy SNP for the IL6R locus and demonstrated that each allele corresponds to approximately 20 ng/mL higher circulating sIL-6R, directly quantifying the biochemical shift associated with the tagging variant.

A cumulative evidence review across 155 IL6R studies and 80 polymorphisms (Zhang et al., Front Immunol, 2022⁶⁶ Zhang et al., Front Immunol, 2022
Systematic review covering 102 disease associations for IL6R variants) assigned rs4129267 strong-evidence associations with cardiovascular diseases and inflammatory diseases including asthma — the same disease spectrum as rs2228145, as expected from their r²=1 LD.

A notable pharmacological dimension emerged from Key et al. (J Cardiovasc Nurs, 2022)⁷⁷ Key et al. (J Cardiovasc Nurs, 2022)
Adults at cardiovascular risk; cross-sectional study examining inflammatory genotype × psychological stress interactions: rs4129267 genotype moderated the relationship between anxiety and circulating IL-6. The association between anxiety and elevated IL-6 was significant only in CC homozygotes (b=0.243, P<0.001), suggesting the IL6R haplotype shapes not only baseline IL-6 signaling but also IL-6 reactivity to psychosocial stressors.

Practical Actions

Because rs4129267 tags the Asp358Ala functional variant in perfect LD, all clinical implications of rs2228145 apply equally here. TT homozygotes carry two copies of the receptor-shedding haplotype: the same elevated sIL-6R, the same impaired classical signaling, the same reduced CRP, the same increased Th2 susceptibility, and the same highest asthma risk from the IL6R locus.

The cardiovascular paradox is also present: the T-allele haplotype that increases asthma risk simultaneously reduces coronary heart disease risk through impaired classical IL-6 signaling and lower CRP production. CC homozygotes have the highest classical IL-6 signaling activity and are more susceptible to CRP-mediated cardiovascular inflammation.

For CT heterozygotes: effects are intermediate. The allele count dose-response means one copy of the T haplotype partially shifts the IL-6 signaling balance — modest increase in asthma susceptibility, modest reduction in CHD risk, neither effect dominant in isolation.

Interactions

As a tag SNP in perfect LD (r²=1) with rs2228145 (Asp358Ala), rs4129267 and rs2228145 share all documented interactions. The most relevant IL6R haplotype partner on the platform is rs12133641, a deep intronic IL6R variant with partially overlapping cardiovascular-protective and atopic-risk associations. Carriers of risk alleles at both loci may show a more pronounced shift in the classical-versus-trans signaling balance than either variant predicts alone.

The IL6R locus interacts with upstream alarmins and cytokines that drive trans-signaling. IL-33 (rs992969), TSLP, and STAT6 variants that independently increase Th2 polarization can compound with the IL6R T-allele effect — individuals who carry risk alleles across multiple Th2-pathway variants experience additive atopic susceptibility beyond what the IL6R locus alone predicts.